Rheumatoid Arthritis: The Impact of Mental Health on Disease: A Narrative Review
AbstractOver 60% of rheumatoid arthritis (RA) patients achieve a good response after 12  months of treatment when following the European league against rheumatism (EULAR) guidelines for treatment. However, almost half of patients still suffer from moderate to severe disease activity despite this. In addition, mental health problems may remain despite reduced measures of inflammation s ystemically and within joints. Depression is two times more common in RA patients than in the general population, and intriguingly a bi-directional relationship with RA has been shown in cross-sectional studies. Chronic inflammation impa...
Source: Rheumatology and Therapy - June 13, 2020 Category: Rheumatology Source Type: research

Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE
AbstractIntroductionAchievement of remission is a key treatment goal for patients with axial spondyloarthritis (axSpA). C-OPTIMISE assessed achievement of sustained clinical remission in patients with axSpA, including radiographic (r) and non-radiographic (nr) axSpA, during certolizumab pegol (CZP) treatment, and subsequent maintenance of remission following CZP dose continuation, dose reduction or withdrawal. Here, we report outcomes from the first 48  weeks (induction period) of C-OPTIMISE, during which patients received open-label CZP.MethodsC-OPTIMISE (NCT02505542) was a two-part, multicenter, phase 3b study in ad...
Source: Rheumatology and Therapy - June 11, 2020 Category: Rheumatology Source Type: research

Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
ConclusionsIn this interim analysis of OPAL Balance, tofacitinib safety and efficacy in patients with PsA appeared to be consistent with those of the P3 studies. Efficacy was maintained over time.Trial RegistrationClinicalTrials.gov identifier: NCT01976364. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - June 6, 2020 Category: Rheumatology Source Type: research

Enhancement of an Auto-Injector Device for Self-Administration of Etanercept in Patients With Rheumatoid Arthritis Confers Emotional and Functional Benefits
ConclusionsThe auto-injector plus sleeve performed strongly against key attributes even in patients with moderate/severe RA and patients with reduced grip strength. The robust grip improved patient confidence and reduced injection-related anxiety. This may be beneficial in patients who are anxious about self-administration, those new to self-administration, and potentially in patients with reduced hand dexterity as a result of either advanced disease or a painful day. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - June 4, 2020 Category: Rheumatology Source Type: research

Obesity and Psoriatic Arthritis: A Narrative Review
AbstractPatients with psoriatic arthritis (PsA) have a higher burden of cardio-metabolic comorbidities like obesity, hypertension, diabetes, and cardiovascular disease compared to the general population. Adipose tissue is thought to promote a chronic low grade inflammatory state through inflammatory mediators like tumor necrosis factor alpha (TNF α), interleukin-6 (IL-6), leptin, and adiponectin. A higher body mass index (BMI) is a risk factor for development of PsA and affects disease activity and response to therapy including both disease-modifying anti-rheumatic drugs (DMARDs) and tumor necrosis factor inhibitors ...
Source: Rheumatology and Therapy - June 3, 2020 Category: Rheumatology Source Type: research

Systemic Lupus Erythematosus (SLE) Therapy: The Old and the New
AbstractDespite recent improvements in the treatment of systemic lupus erythematosus (SLE), disease activity, comorbidities and drug toxicity significantly contribute to the risk of progressive irreversible damage accrual and increased mortality in patients with this chronic disease. Moreover, even lupus patients in remission often report residual symptoms, such as fatigue, which have a considerable impact on their health-related quality of life. In recent decades, SLE treatment has moved from the use of hydroxychloroquine, systemic glucocorticosteroids and conventional immunosuppressive drugs to biologic agents, of which ...
Source: Rheumatology and Therapy - June 2, 2020 Category: Rheumatology Source Type: research

Rheumatology Care in the Face of COVID-19
(Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - May 29, 2020 Category: Rheumatology Source Type: research

Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns Among Rheumatologists in Europe and Japan
AbstractIntroductionTumor necrosis factor inhibitors (TNFi) are commonly used as first-line therapy (biologic disease-modifying antirheumatic drug [bDMARD] and targeted synthetic DMARD [tsDMARD]: defined as targeted therapy) for patients with moderate-to-severe rheumatoid arthritis (RA), usually combined with conventional synthetic DMARDs (csDMARDs) but sometimes as monotherapy. If treatment fails, patients cycle to another TNFi (cycling) or switch to a targeted therapy with a different mode of action (MOA; switching). The study aimed to examine prescribing patterns and reasons for current RA treatment practice in Europe (...
Source: Rheumatology and Therapy - May 21, 2020 Category: Rheumatology Source Type: research

Association Between Nursing Support Levels and Effectiveness of Golimumab in the Management of Patients with Rheumatologic Diseases
ConclusionsThis prospective open-label study has confirmed the short-term effectiveness of golimumab in three rheumatological diseases, with most of the patients qualifying for reimbursement renewal. The limited sample size and the fact that the vast majority of patients benefited from an intense nursing support did not allow drawing definite conclusions concerning the impact of the nursing level on the treatment effectiveness and changes in the disease activity. Nurses seem however to play a crucial role in this short-term study but this remains to be confirmed in a longer-term study. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - May 2, 2020 Category: Rheumatology Source Type: research

Use and Switching of Biologic Therapy in Patients with Non-Radiographic Axial Spondyloarthritis: A Patient and Provider Survey in the United States
ConclusionsThis study suggests that around 60% of nr-axSpA patients were receiving biologic therapy prior to the approval of certolizumab pegol. Switching of biologics is frequent in nr-axSpA patients and is usually due to lack of efficacy, loss or response, and effort to accomplish remission. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - April 23, 2020 Category: Rheumatology Source Type: research

Depression in Psoriatic Arthritis: Dimensional Aspects and Link with Systemic Inflammation
AbstractStudying comorbidities in patients with psoriatic arthritis (PsA) provides a better understanding of the extended burden of the disease. Depression and anxiety are well recognized but understudied comorbidities in patients with PsA. The prevalence of depression is significantly higher in this patient population than in the general population, with far reaching consequences in terms of long-term quality of life. Over the past few years there has been an increasing interest in the link between inflammation and depression, with several novel studies being conducted. Recent evidence suggests a significant improvement o...
Source: Rheumatology and Therapy - April 22, 2020 Category: Rheumatology Source Type: research

Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns for Rheumatoid Arthritis Among United States Physicians
This study examined patient characteristics, prescribing patterns and treatment practice for RA in the United States.MethodsData were from the Adelphi Disease Specific Programme (Q2 –Q3 2016). Rheumatologists completed a survey and patient record forms for adult patients with RA who had received ≥ 1 targeted therapy. Patients were grouped by class of first-used targeted therapy, and monotherapy vs. combination therapy. TNFi patients who received ≥ 1 targeted thera py were classified as cyclers or switchers. Univariate analyses compared patient characteristics and physician factors ac...
Source: Rheumatology and Therapy - April 21, 2020 Category: Rheumatology Source Type: research

Psoriatic Arthritis and Diabetes Mellitus: A Narrative Review
ConclusionsPatients affected by PsA have a higher prevalence of type 2 DM compared with the general population. The mechanism linking PsA with DM has not been completely clarified, but some of the principal mediators could be TNF- α and adipokine, especially adiponectin and omentin. Apremilast and TNF-α inhibitor may have a favorable effect and could be safely used in patients with DM. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - April 18, 2020 Category: Rheumatology Source Type: research

Golimumab as the First-, Second-, or at Least Third-Line Biologic Agent in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis: Post Hoc Analysis of a Noninterventional Study in Germany
AbstractIntroductionWhile golimumab (GLM) has demonstrated efficacy in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) in several randomized clinical trials with biologic-na ïve patients, observational data from biologic-experienced patients are sparse. We aimed to assess the effectiveness of GLM used as the first-, second-, or at least third-line biologic agent in RA, PsA, and AS patients in a real-world setting.MethodsPost hoc analysis of the noninterventional, prospective, 24-month GO-NICE study of RA, PsA, and AS patients who initiated GLM 50  mg subcutaneously once month...
Source: Rheumatology and Therapy - April 17, 2020 Category: Rheumatology Source Type: research

Review Article: Is Wnt Signaling an Attractive Target for the Treatment of Osteoarthritis?
AbstractOsteoarthritis is the most common chronic joint disease affecting millions of people worldwide and a leading cause of pain and disability. Increasing incidence of obesity and aging of the population are two factors that suggest that the impact of osteoarthritis will further increase at the society level. Currently, there are no drugs available that can manage both structural damage to the joint or the associated pain. Increasing evidence supports the view that the Wnt signaling pathway plays an important role in this disease. The current concept, based on genetic and functional studies, indicates that tight regulat...
Source: Rheumatology and Therapy - April 10, 2020 Category: Rheumatology Source Type: research

The Impact of Comorbidity on Patient-Reported Outcomes in Psoriatic Arthritis: A Systematic Literature Review
ConclusionsThe prevalence and impact of medical comorbidity on PROs are very high in patients with PsA. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - April 8, 2020 Category: Rheumatology Source Type: research

Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corrona Rheumatoid Arthritis Registry
ConclusionsA considerable proportion of patients initiating TCZ discontinued or decreased their MTX dose after TCZ initiation. Improvements in disease activity and functionality were observed in patients who decreased or stopped MTX. This real-world study confirmed prior observations that discontinuing or decreasing MTX may be a treatment strategy for patients initiating TCZ combination therapy.Trial RegistrationClinicalTrials.gov identifier, NCT01402661. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - March 30, 2020 Category: Rheumatology Source Type: research

Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic
The objective of this study was to compare persistence with subcutaneous (SC) tocilizumab to persistence with other SC bDMARDs when these drugs are used as subsequent-line therapy in RA patients who previously received  ≥ 1 bDMARD.MethodsRA patients in a US administrative claims database who initiated a second- or subsequent-line SC bDMARD between January 1, 2012 and June 30, 2017 (initiation date  = index date) were included. Persistence was defined as the number of days between the bDMARD initiation date and (1) the last supplied day of medication fill (primary) or (2) the day on which the ...
Source: Rheumatology and Therapy - March 29, 2020 Category: Rheumatology Source Type: research

Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial
The objective of this study was to assess efficacy and safety of repository corticotropin injection (RCI) in subjects with active rheumatoid arthritis (RA) despite treatment with a corticosteroid and one or two disease-modifying antirheumatic drugs (DMARDs).MethodsAll subjects received open-label RCI (80 U) twice weekly for 12  weeks (part 1); only those with low disease activity [LDA; i.e., Disease Activity Score 28 joint count and erythrocyte sedimentation rate (DAS28-ESR) 
Source: Rheumatology and Therapy - March 17, 2020 Category: Rheumatology Source Type: research

Effect of Golimumab Dose Escalation in Japanese Patients With Rheumatoid Arthritis: Post-Hoc Analysis of Post-Marketing Surveillance Data
ConclusionIn real-world clinical practice, improvement of disease activity was observed after uptitration of golimumab from 50 to 100  mg regardless of the timing. Male patients and biologic-naive patients were more likely to respond to dose escalation of golimumab.Trial RegistrationUMIN-CTR, Identifier: UMIN000015895. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - February 29, 2020 Category: Rheumatology Source Type: research

Topical Diclofenac, an Efficacious Treatment for Osteoarthritis: A Narrative Review
AbstractMultiple head-to-head trials have demonstrated that topical nonsteroidal anti-inflammatory drugs (NSAIDs), including topical diclofenac, provide at least equivalent analgesia, improvement in physical function, and reduction of stiffness compared with oral NSAIDs in osteoarthritis and have fewer systemic adverse events. While efficacy of topical diclofenac in osteoarthritis is well established, understanding of the time to onset of action, duration of effect, and the minimum effective concentration is limited. Factors likely to influence these parameters include drug penetration and localization. Diclofenac concentr...
Source: Rheumatology and Therapy - February 21, 2020 Category: Rheumatology Source Type: research

Improvement of Function and Its Determinants in a Group of Axial Spondyloarthritis Patients Treated with TNF Inhibitors: A Real-Life Study
ConclusionsOur results showed that in real-life settings, patients improve in BASMI and BASFI. Furthermore, factors associated with this improvement were identified. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - February 15, 2020 Category: Rheumatology Source Type: research

Characteristics and Symptom Severity of Patients Reporting Systemic Lupus Erythematosus in the PatientsLikeMe Online Health Community: A Retrospective Observational Study
ConclusionsAge, sex, and race of patients in the PLM SLE community are broadly consistent with characteristics of the general SLE population in the United States. The PLM SLE population may provide valuable data on self-reported patient experience.Plain Language SummaryPlain language summary available for this article. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - February 1, 2020 Category: Rheumatology Source Type: research

Clinical, Economic, and Humanistic Burden Associated With Delayed Diagnosis of Axial Spondyloarthritis: A Systematic Review
ConclusionsDelayed axSpA diagnosis was associated with more functional impairment, higher healthcare costs, and worse quality of life, highlighting the importance of early recognition of axSpA to reduce extensive burden on patients and society.Plain Language SummaryPlain language summary available for this article. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - January 21, 2020 Category: Rheumatology Source Type: research

Pharmacokinetics, Pharmacodynamics and Safety of Belimumab in Chinese Patients with Systemic Lupus Erythematosus: A Phase  I, Open-Label Study
ConclusionPK of a single belimumab 10  mg/kg IV dose in Chinese patients with SLE were similar to those observed previously in Japanese and American (white and African-American) patients with SLE. PD results were consistent with belimumab inhibiting BLyS, and belimumab was well tolerated. These data support the use of belimumab in Chin ese patients with SLE.Trial RegistrationClinicalTrials.gov identifier, NCT02880852. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - January 17, 2020 Category: Rheumatology Source Type: research

Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?
The objective of this narrative review was to explore the reasons for nonmedical switch failure or discontinuation and the role of the nocebo effect among patients with inflammatory rheumatic and gastrointestinal diseases who switched from an originator biologic to its biosimilar. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - January 16, 2020 Category: Rheumatology Source Type: research

Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials
AbstractIntroductionThe Janus kinase (JAK) inhibitor therapeutic class has shown significant clinical benefit in the treatment of rheumatoid arthritis (RA). We sought to gain insight into the mode of action and immunological effects of filgotinib, a JAK1 selective inhibitor, in active RA by analyzing secreted and cell-based biomarkers key to RA pathophysiology in two phase 2b trials of filgotinib in active RA.MethodsImmune cell subsets and 34 serum biomarkers were analyzed longitudinally over 12  weeks using blood samples collected from patients with active RA receiving filgotinib (100 or 200 mg once daily) or pl...
Source: Rheumatology and Therapy - January 7, 2020 Category: Rheumatology Source Type: research

Comparative Cost per Response for 4 Clinical Endpoints with Tocilizumab Monotherapy vs Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid Arthritis
The objective of this study was to compare drug and adverse event costs and cost per successful clinical response with tocilizumab (TCZ) monotherapy vs adalimumab (ADA) monotherapy in patients with RA in a phase  4 clinical trial.MethodsPatients received either TCZ intravenously every 4  weeks or ADA subcutaneously every 2 weeks for 24 weeks. Drug and administration costs were based on wholesale acquisition costs and the Centers for Medicare and Medicaid, respectively. Outcomes included patient-level drug costs, cost of hospitalization due to adverse events, and cost per respons e. Cost per response was...
Source: Rheumatology and Therapy - January 6, 2020 Category: Rheumatology Source Type: research

Autoimmunity and Inflammation Link to Cardiovascular Disease Risk in Rheumatoid Arthritis
AbstractRheumatoid arthritis (RA) patients have a 50% increased risk of cardiovascular (CV)-related morbidity and mortality. This excess CV risk is closely linked to RA disease severity and chronic inflammation, hence is largely underestimated by traditional risk calculators such as the Framingham Risk Score. Epidemiological studies have shown that patients with RA are more likely to have silent ischemic heart disease, develop heart failure, and experience sudden death compared with controls. Elevations in pro-inflammatory cytokines, circulating autoantibodies, and specific T cell subsets, are believed to drive these findi...
Source: Rheumatology and Therapy - December 18, 2019 Category: Rheumatology Source Type: research

A Comparative Study to Assess the Efficacy, Safety, and Immunogenicity of YLB113 and the Etanercept Reference Product for the Treatment of Patients with Rheumatoid Arthritis
ConclusionsThis study demonstrated biosimilarity of YLB113 to the RP regarding efficacy, safety, and immunogenicity in patients with moderate-to-severe RA. Based on the same mechanism of action, biosimilarity could be extrapolated to other therapeutic indications approved for etanercept.Trial registrationEudraCT Number: 2015-002,809-12. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - December 12, 2019 Category: Rheumatology Source Type: research

Looking Back on 2019 in Rheumatology and What to Expect from 2020
(Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - December 10, 2019 Category: Rheumatology Source Type: research

Comment on “A Randomized, Double-Blind, Non-inferiority Study of Febuxostat Versus Allopurinol in Hyperuricemic Chinese Subjects with or Without Gout”
(Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - December 10, 2019 Category: Rheumatology Source Type: research

Cardiovascular Comorbidities in Psoriatic Disease
AbstractPsoriatic disease (PsD) is a multisystem inflammatory disorder with a high prevalence of cardiovascular (CV) risk factors contributing to accelerated atherosclerosis and its sequelae. Imaging studies, notably with ultrasound, computed tomography, and positron emission tomography (PET) scanning have confirmed significant atherosclerotic change with plaque formation and vessel stenosis. Atherosclerosis is likely driven by a combination of traditional risk factors which occur more frequently in PsD and by systemic inflammation with associated pro-inflammatory cytokine production. While the mechanisms driving atheroscl...
Source: Rheumatology and Therapy - December 7, 2019 Category: Rheumatology Source Type: research

Risk of Malignancies in Patients with Rheumatoid Arthritis Treated with Rituximab: Analyses of Global Postmarketing Safety Data and Long-Term Clinical Trial Data
ConclusionsAnalyses of the global postmarketing safety database and long-term clinical trial data showed no evidence of an increased risk of malignancy of any type following rituximab treatment in patients with RA.FundingF. Hoffmann-La Roche Ltd. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - November 21, 2019 Category: Rheumatology Source Type: research

Retrospective Analysis of the Impact of Adalimumab Initiation on Corticosteroid Utilization and Medical Costs Among Biologic-Na ïve Patients with Rheumatoid Arthritis
The objective was to examine the impact of adalimumab (ADA) initiation on steroid utilization and non-drug medical costs among patients with RA.MethodsA retrospective analysis was conducted among adult RA patients initiating ADA as the initial biologic in the MarketScan Database (2012 –2016). Study outcomes included whether oral/injectable steroids were used, daily dose, dosage categories (
Source: Rheumatology and Therapy - November 18, 2019 Category: Rheumatology Source Type: research

Characterizing Disease Manifestations and Treatment Patterns Among Adults with Systemic Sclerosis: A Retrospective Analysis of a US Healthcare Claims Population
ConclusionOne-third of patients with SSc in the healthcare claims population received IMTs during the first year after diagnosis. However, patients who received IMTs had disease manifestations similar to those of the overall SSc healthcare claims population. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - November 16, 2019 Category: Rheumatology Source Type: research

Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study
This study evaluated spebrutinib pharmacology and mechanism of action over a 4-week treatment period in patients with active rheumatoid arthritis (RA).MethodsPrimary human B cells, T cells, natural killer cells, macrophages, dendritic cells, basophils, and osteoclasts were treated with spebrutinib in vitro. Clinical pharmacodynamics were studied in 47 patients with active RA on background methotrexate therapy randomized to oral spebrutinib 375  mg/day or placebo.ResultsIn vitro, spebrutinib inhibited B-cell proliferation more potently than T-cell proliferation and reduced both lymphoid and myeloid cytokine production ...
Source: Rheumatology and Therapy - November 13, 2019 Category: Rheumatology Source Type: research

Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis
ConclusionsIn clinical practice, TNFi efficacy is improved with concomitant MTX in the second and third line. In the third/fourth line, patients are likely to achieve similar efficacy with tofacitinib monotherapy, or TNFi or tofacitinib in combination with MTX.FundingPfizer Inc (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - November 9, 2019 Category: Rheumatology Source Type: research

Assessing Physical Activity and Sleep in Axial Spondyloarthritis: Measuring the Gap
AbstractPatients with axial spondyloarthritis (axSpA) frequently report pain, stiffness, fatigue, and sleep problems, which may lead to impaired physical activity. The majority of reported-on measures evaluating physical activity and sleep disturbance in axSpA are self-reported questionnaires, which can be impacted by patient recall (reporting bias). One objective measure, polysomnography, has been employed to evaluate sleep in patients with axSpA; however, it is an intrusive measure and cannot be used over the long term. More convenient objective measures are therefore needed to allow for the long-term assessment of both ...
Source: Rheumatology and Therapy - October 31, 2019 Category: Rheumatology Source Type: research

Treat-To-Target and Treat-To-Budget in Rheumatoid Arthritis: Measuring the Value of Individual Therapeutic Interventions
AbstractTreat-to-target (T2T) and dose tapering after obtaining the therapeutic objective (called “treat-to-budget”-T2B-in this Commentary) are the two most commonly used therapeutic strategies in rheumatoid arthritis. In theory, both strategies could add value to the healthcare system, although they are focused on different objectives: T2T strategy improves outcomes but increases short-term costs, while the cost savings obtained through T2B are associated with higher relapse rates. The systematic implementation of both strategies must be founded on solid evidence of their effectiveness and efficiency. However,...
Source: Rheumatology and Therapy - October 30, 2019 Category: Rheumatology Source Type: research

Physical and Emotional Burden of Rheumatoid Arthritis: Data from RA Matters, a Web-Based Survey of Patients and Healthcare Professionals
ConclusionPatients and HCPs feel that the physical and emotional impact of RA is not well understood by people without the disease. In RA treatment decisions, patients ’ personal goals and patient-reported outcomes should be taken into consideration along with clinical targets.FundingEli Lilly and Company (Indianapolis, IN, USA). (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - October 28, 2019 Category: Rheumatology Source Type: research

Risk of Potential Glucocorticoid-Related Adverse Events in Patients with Giant Cell Arteritis: Results from a USA-Based Electronic Health Records Database
ConclusionsIn patients with GCA, potential GC-related AEs increased with higher daily oral GC doses. This highlights the need for effective therapies that reduce GC exposure and toxicity.FundingGenentech, Inc. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - October 26, 2019 Category: Rheumatology Source Type: research

Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE)
ConclusionThis analysis indicates a trend towards improved disease activity and physical function with abatacept versus adalimumab in patients with seropositive, erosive early RA.Trial RegistrationClinicalTrials.gov NCT00929864.FundingBristol-Myers Squibb. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - October 22, 2019 Category: Rheumatology Source Type: research

Changes in Opioid Utilization Following Tumor Necrosis Factor Inhibitor Initiation in Patients with Rheumatoid Arthritis
ConclusionsThis real-world study of commercially insured patients with RA suggests that opioid use among these  patients is prevalent. There was a small decrease in overall opioid utilization after TNFi initiation. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - October 18, 2019 Category: Rheumatology Source Type: research

A Randomized, Double-Blind, Non-Inferiority Study of Febuxostat Versus Allopurinol in Hyperuricemic Chinese Subjects With or Without Gout
ConclusionsUsing a novel dose-titration method, although the primary endpoint of non-inferiority of febuxostat 40  mg/day versus allopurinol 300 mg/day was not reached, non-inferiority and superiority of febuxostat 60 mg/day and 80 mg/day versus allopurinol 300 mg/day was demonstrated at weeks 16 and 24, respectively. Febuxostat demonstrated an acceptable tolerability profile in the treatment of hyperurice mia in Chinese subjects with or without gout.Trial RegistrationJapicCTI-132106.FundingAstellas Pharma Global Development, Inc. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - September 17, 2019 Category: Rheumatology Source Type: research

Comparative Disease Burden in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from Two Corrona Registries
ConclusionsDisease burden in patients with PsA or axSpA was comparable to or greater than that in patients with RA on the basis of common patient-reported outcome measures but appeared lower when assessed using RA disease activity measures, suggesting that disease-specific approaches to care are needed to optimize disease management.FundingThis study was sponsored by Corrona, LLC, and financial support was provided by Novartis. The Rapid Service Fee was funded by Novartis.Plain Language SummaryPlain language summary available for this article. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - September 16, 2019 Category: Rheumatology Source Type: research

Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients
ConclusionsIn our study, based on clinical practice, a sustained VLDA was achieved in 17.5% and a sustained remission according to the DAPSA criteria in 30% of patients with PsA. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - August 19, 2019 Category: Rheumatology Source Type: research

Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study
ConclusionAmong 319 patients who completed this 2-year extension of two global phase IIb studies, peficitinib 100  mg once daily demonstrated a stable safety profile and sustained effectiveness in patients with moderate-to-severe RA.Trial RegistrationClinicalTrials.gov identifier, NCT01711814. Registered 19 October 2012.FundingAstellas Pharma Global Development, Inc. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - August 13, 2019 Category: Rheumatology Source Type: research

New Insights in Physical Therapy and Rehabilitation in Axial Spondyloarthritis: A Review
AbstractAxial spondyloarthritis (axSpA) is a chronic and inflammatory rheumatic disease characterized by pain, structural and functional impairments, and reduced mobility and potential deformity of the axial skeleton. Treatment of axSpA includes pharmacological and non-pharmacological therapy. However, in the biologic era, unmet needs still remain for patients intolerant to or non-responders to biologic drugs and despite the development of new treatments, physical therapy and rehabilitation are of crucial importance in the management of axSpA patients. The aim of this manuscript is to review the current evidence on the ass...
Source: Rheumatology and Therapy - August 13, 2019 Category: Rheumatology Source Type: research

Patient Perceptions of Unmet Medical Need in Rheumatoid Arthritis: A Cross-Sectional Survey in the USA
ConclusionsResults from this real-world survey suggest that three-fourths of RA patients are not satisfied with treatments, which include bDMARDs. Patients continued to experience bothersome symptoms that impacted their daily activities and life. There remains a need for improved disease management among currently treated RA patients.FundingEli Lilly and Company (Indianapolis, IN, USA). (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - August 6, 2019 Category: Rheumatology Source Type: research